1. Inicio
  2. Publicaciones
  3. Safety Profile of Systemic Therapy for the Management of Psoriasis in Patients With Diabetes Mellitus: Data From the BIOBADADERM Prospective Cohort

Safety Profile of Systemic Therapy for the Management of Psoriasis in Patients With Diabetes Mellitus: Data From the BIOBADADERM Prospective Cohort

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Lluch-Galcerá J.J.
  • Carrascosa J.M.
  • González-Quesada A.
  • Rivera Díaz R.
  • Llamas-Velasco M.
  • Herrera-Acosta E.
  • Belinchón I.
  • Gómez García F.J.
  • Baniandrés-Rodríguez O.
  • Ruiz-Genao D.P.
  • López-Estebaranz J.L.
  • Rodríguez Fernández-Freire L.
  • de la Cueva Dobao P.
  • Ferrán Farrés M.
  • Mateu Puchades A.
  • Ruiz-Villaverde R.
  • Riera-Monroig J.
  • Ara-Martín M.
  • Roncero Riesco M.
  • Gracia-Cazaña T.
  • Abalde Pintos M.T.
  • García-Donoso C.
  • del Alcázar E.
  • Santamaría C.
  • Suárez Pérez J.
  • Rodríguez Sánchez B.
  • Díez-Madueño K.
  • Lezcano Biosca V.
  • Morales Callaghan A.M.
  • Salgado-Boquete L.
  • Montes-Torres A.
  • González-Sixto B.
  • Descalzo M.Á.
  • García-Doval I.

Grupos

Abstract

Background and objective Patients with psoriasis and concomitant diabetes mellitus (DM) may be vulnerable to diabetes-related adverse events (DM-AEs). This study aimed to evaluate the incidence of DM-AEs associated with systemic treatments used in patients with psoriasis and DM. Methods We conducted a prospective cohort study using data from the BIOBADADERM registry. We calculated incidence rates (IRs) of DM-AEs for each systemic treatment class, including biologics (tumor necrosis factor [TNF] inhibitors, interleukin [IL]-12/23 inhibitors, IL-17 inhibitors, and IL-23 inhibitors), conventional systemic therapies (methotrexate [MTX], cyclosporine, and acitretin), and apremilast (APR). The primary outcome was the adjusted incidence rate ratio (aIRR) for DM-AEs comparing patients receiving MTX with those receiving other systemic therapies using Poisson regression models adjusted for potential confounders. Results The study included 732 patients, 1401 treatment cycles, and 2865 person-years (PYs) of follow-up. APR (aIRR, 0.30; 95% CI, 0.10–0.60) was associated with a significantly lower risk of DM-AEs compared with MTX. Cyclosporine (aIRR, 7.50; 95% CI, 3.30–17.30) and acitretin (aIRR, 2.10; 95% CI, 1.20–3.70) were associated with a higher risk compared with MTX. Conclusions Among patients with psoriasis and DM, APR was associated with a lower incidence of DM-AEs, whereas cyclosporine and acitretin were associated with higher incidences compared with MTX. © 2026 AEDV.

Datos de la publicación

ISSN/ISSNe:
0001-7310, 1578-2190

Actas Dermo-Sifiliograficas  ELSEVIER ESPANA

Tipo:
Article
Páginas:
-
PubMed:
42177023
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
0,279 SCImago ℠
Cuartil:
Q3 SCImago ℠

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • acitretin; adalimumab; apremilast; bimekizumab; biosimilar agent; brodalumab; certolizumab pegol; creatinine; cyclosporine; cytokine receptor antagonist; etanercept; guselkumab; infliximab; interleukin 12 inhibitor; interleukin 17 inhibitor; interleukin 23 inhibitor; ixekizumab; methotrexate; risankizumab; secukinumab; tildrakizumab; tumor necrosis factor inhibitor; unclassified drug; ustekinumab; adult; aged; Article; clinical outcome; cohort analysis; comparative study; diabetes mellitus; diabetic complication; drug safety; erythrodermic psoriasis; female; follow up; generalized pustular psoriasis; guttate psoriasis; heart failure; human; hyperglycemia; hypertension; hypertriglyceridemia; incidence; major clinical study; male; multicenter study; patient registry; phototherapy; prospective study; psoriasis; Psoriasis Area and Severity Index; psoriasis vulgaris; psoriatic arthritis; pustulosis palmoplantaris; systemic therapy; treatment duration; unspecified side effect

Cita

Compartir